Molecular and Cellular PharmacologyCombination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-κB
Introduction
Prostate cancer is the most commonly diagnosed cancer in men. Unfortunately, there is no effective treatment for prostate cancer (Jemal et al., 2002). Docetaxel, a semi-synthetic taxoid produced from the needles of the European yew (Taxus baccata) tree, is an antineoplastic drug. As a chemotherapeutic agent, docetaxel is one of the most important new and active chemotherapeutic agents developed in the recent years, and has a potential activity against human solid tumors including prostate cancers that are refractory to conventional anti-cancer agents (Diaz-Rubio, 2004). However, the use of high dose docetaxel always induced toxic reactions, and significant toxicity had precluded the use of docetaxel as a monotherapy for cancer (Cortes and Pazdur, 1995, Fossella et al., 2000, 2004; Tedesco et al., 2004). Since low or moderate doses of docetaxel have no significant antitumor activity in patients (Ferraresi et al., 2000, Okada et al., 1999, Ryan et al., 2002), ways to reduce the dose of docetaxel without affecting its antitumor activity should be examined. In this regard, dietary supplements as well as phytotherapeutic agents with anti-cancer efficacy and least toxicity to normal tissues are suggested as possible candidates to be investigated for their synergistic efficacy in combination with anti-cancer drugs (Agarwal, 2000, Hong and Sporn, 1997, Kelloff, 2000, Sporn and Suh, 2000).
NF-κB mediates chemotherapeutic resistance through the expression of genes participating in malignant conversion and tumor promotion (Garg and Aggarwal, 2002, Greten et al., 2004, Pikarsky et al., 2004a, Pikarsky et al., 2004b). In primary prostate cancer tissue samples, constitutive NF-κB activity has been suggested to have prognostic importance for a subset of primary tumors (Suh and Rabson, 2004). Moreover, NF-κB was shown to be constitutively activated in human androgenin dependent prostate cancer cell lines (Palayoor et al., 1999). In addition, several reports have suggested that chemotherapeutic-induced NF-κB activity mediates survival signals that counteract apoptosis (Dong et al., 2002, Huang et al., 2000, Oyaizu et al., 2001, Uzzo et al., 2002), and it may be critical in the development of drug resistance in cancer cells (Dong et al., 2002). Therefore, several agents that are able to inhibit NF-κB might be considered as an adjuvant approach in combination with chemotherapeutics for lung cancer (Oyaizu et al., 2001), prostate cancer (Uzzo et al., 2002), pancreatic cancer (Zhang et al., 2003), breast cancer (Weldon et al., 2001), and colon cancer (Yance and Sagar, 2006).
Ginseng has been used in Asian countries for the treatment and prevention of various diseases, including cancer (Ryan et al., 2002). People consuming ginseng are at lower risk for stomach, lung, liver, pancreas, ovary, and colon cancers (Ferraresi et al., 2000). A novel ginsenoside, Rg3 from Panax notoginseng has an anti-cancer activity (Mabuchi et al., 2004). It was previously found that Rg3 has an inhibitory effect on the inactivation of NF-κB, thus inhibiting colon cancer cell growth (Anil et al., 2002). In this study, we evaluated Rg3 for its effects against prostate cancer, emphasizing combination therapy, and inhibition of NF-κB as a molecular mechanism.
Section snippets
Materials
Rg3 (structure shown in Fig. 1A), a major ginsenoside derived from heat-processed ginseng (Sun ginseng), was prepared and purified as described previously (Kim et al., 2000). Docetaxel was produced by the procedure of semi-synthesis, and purified. Briefly, crude docetaxel was obtained from semi-synthesis by the reaction of dehydroxybaccatin III with (3R,4S)-1-t-boc-3-triethylsilyloxy-4-phenylazetidin-2-one, and then purified by recrystallization with MeOH/DW(methanol/distilled water) solution.
Effect of the combination of Rg3 and docetaxel on the NF-κB activation
We were interested whether Rg3 inhibits prostate cancer cell growth by inactivation of NF-κB because activation of NF-κB is critical in prostate cancer cell survival and resistance against chemotherapeutics. Constituted activation of NF-κB was observed in prostate, and the treatment of docetaxel slightly changed (either increase or decrease) the NF-κB DNA binding activity by 1 or 5 nM of docetaxel in LNCaP, DU145, PC-3, and then decreased by 10 nM docetaxel as similar to a previous report (Lee et
Discussion
The present study indicates that Rg3 strongly augments the growth inhibitory effect of docetaxel and other therapeutic agents on prostate cancer cell by inactivation of NF-κB. As a chemotherapeutic agent, docetaxel has one of the most potential activities against human solid tumors including prostate cancers (Diaz-Rubio, 2004). However, the use of high dose docetaxel induces significant toxicity (Cortes and Pazdur, 1995, Fossella et al., 2000, 2004; Tedesco et al., 2004), but low or moderate
Acknowledgments
This work was supported by the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korean Government (MOST) (R13-2008-001-00000-00), and by the grant of the Korean Ministry of Education Science and Technology (The regional Core Research program/Chungbuk BIT Research-Oriental University Consortium).
References (58)
Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents
Biochem. Pharmacol.
(2000)- et al.
Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells
Biochem. Pharmacol.
(2002) - et al.
The chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
J. Biol. Chem.
(2000) - et al.
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer
Cell
(2004) - et al.
DNA damaging agents induce expression of Fas Ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1. Mol
Cell.
(1998) - et al.
Inhibitory effects of the ginsenoside Rg3 on phorbol ester-induced cyclooxygenase-2 expression, NF-kappaB activation and tumor promotion
Mutat. Res.
(2003) - et al.
Growth inhibitory effects of obovatol through induction of apoptopic cell death in prostate and colon cancer by blocking of NF-κB
Eur. J. Pharmacol.
(2008) - et al.
Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer
Urol. Oncol.
(2001) - et al.
Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial
J. Hepatol.
(1998) The Rel/NF-κB family: friend and foe
Trends Biochem. Sci.
(2000)
2-Methoxyestradiol induces G2-M arrest and apoptosis in prostate cancer
Biochem. Biophys. Res. Commun.
Combination of proteasomal inhibitors lactacystin and MG132 induced synergistic apoptosis in prostate cancer cells
Neoplasia
Innovative treatment programs against cancer: II. Nuclear factor-κB (NF-κB) as a molecular target
Biochem. Pharmacol.
NF-kappa B-mediated chemoresistance in breast cancer cells
Surgery
Guns ES.Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models
J. Urol.
Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo
Clin. Cancer Res.
An essential role for NF-κB in preventing TNF-α induced cell death
Science
Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer
Oncol. Res.
Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis
Clin. Cancer Res.
In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer
Cancer Res.
Thiacremonone augments chemotherapeutic agent-induced growth inhibition in human colon cancer cells through inactivation of nuclear factor-{κ}B
Mol. Cancer Res.
Constitutive nuclear factor-κB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells
J. Clin. Invest.
Control of apoptosis by Rel/NF-κB transcription factors
Oncogene
Magnolol attenuates VCAM-1 expression in vitro in TNF-alpha-treated human aortic endothelial cells and in vivo in the aorta of cholesterol-fed rabbits
Br. J. Pharmacol.
Docetaxel. J. Clin. Oncol.
New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers
Oncol.Rev.
The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis
Oncogene
Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB
Cancer Res.
Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study
Am. J. Clin. Oncol.
Cited by (121)
In vitro biological evaluation of Steroidal Saponins from seeds of Crotalaria verrucosa L. for cancer studies
2024, Environmental AdvancesNanomaterials induce different levels of oxidative stress, depending on the used model system: Comparison of in vitro and in vivo effects
2021, Science of the Total EnvironmentProstate cancer: Therapeutic prospect with herbal medicine
2021, Current Research in Pharmacology and Drug DiscoveryThe effects of cytarabine combined with ginsenoside compound K synergistically induce DNA damage in acute myeloid leukemia cells
2020, Biomedicine and PharmacotherapyCitation Excerpt :Therefore, it is important to improve the effective therapies of ara-C for the treatment of AML. Ginseng is a well-known herbal medicine, and some ginsenosides are often used to exhibit anti-cancer activity to inhibit angiogenesis, invasion and DNA synthesis, as well as inhibit cell viability and induce cell death, either alone or in combination with anticancer drugs to enhance chemotherapy [12–18]. Compound K (CK) is the major metabolic product of protopanaxatriol in the human intestinal tract and is one of the most studied saponins; it has unique pharmacological activities, specifically as an anti-cancer agent [19–22].